Adlego Biomedical AB is a privately owned company which is focused on drug development. Because Adlego is not liaised with any pharmaceutical company or other CROs, customers are always guaranteed honest project discussions and reports. Medical Product Agencies rely on the independence and integrity of Adlego!
We are operating in a state-of-the-art facility which has the flexibility needed to take on short-term basic DMPK studies as well as demanding long-term projects at bio safety level 3. Our customers benefit from the flexible organisation of Adlego Biomedical and they do not need to pay unnecessary overheads for services of the highest quality. We collaborate with a complete range of companies to cover all parts of preclinical drug development.
AQPS business acts towards companies engaged in development of drugs, with the objective to evaluate the effect and security of product candidates and reach market via registration and approval of the final pharma product. AQPS have specialists in areas of formulation, manufacturing and quality assurance of drugs and drug candidates.
Eurocine Vaccines is a pharmaceutical company. The company develops vaccines using its proprietary technology platform Endocine™, which vaccines are subsequently licensed to partners for further development and commercialization. Development is carried out in cooperation with other companies in the industry. The technology platform Endocine™ is also offered to other companies for development within certain indications. The head office is located in Solna.
GU Ventures' mission is to commercialize and fund research related to the University of Gothenburg. The incubator is top-ranked by UBI Global as one of the world's 20 leading university-controlled incubators and has since its inception in 1995 developed 200 new business ideas. The portfolio consists of 70 holdings distributed within Life Science and Tech.
The company conducts verification and development work aimed at commercial exploitation of projects and knowledge developed within the framework of research activities at the MIVAC center at the University of Gothenburg. The research area includes mucosal biology and vaccines and aims to develop vaccine formulations, to strengthen and inhibit immunity that emanates from the mucous membranes. Vaccination can thus be used to provide protection against infectious diseases and treatment of autoimmune diseases, such as type 1 diabetes and multiple sclerosis. At the same time, the company owns shares in the companies developed from MIVAC Development AB, ie Alzinova AB and Toleranzia AB
Valneva is a specialty vaccine company providing prevention against diseases with major unmet medical needs. Our commercial business has two successful vaccines for travelers and our focused pipeline includes the only Lyme disease vaccine candidate in clinical development today, a single-shot chikungunya vaccine candidate and an inactivated vaccine candidate against COVID-19. Our vision is to contribute to a world in which no one dies or suffers from a vaccine-preventable disease.